Pharmacy Medical News about chronic pain; opiates; monitoring

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effective Monitoring of Opiates in Chronic Pain Patients
Practical Pain Management, 09/10/09

Evans M et al. – Earlier this year, the U.S. Food and Drug Administration (FDA) announced its intent to require manufacturers of two dozen opioid formulations to construct detailed Risk Evaluation and Mitigation Strategies (REMS) for their products in order to verify that their benefits to pain management continue to outweigh the potential risks associated with abuse and misuse. In addition to individualized REMS for certain branded and generic drugs, the FDA also plans to issue a formal REMS for the opioid drug class as a whole, which may take up to a year to develop.

<< Previous
Migraines with and without aura and their response to preventive...

Next >>
Population Pharmacokinetics of Intramuscular Paliperidone...